C4 Therapeutics (CCCC) Return on Capital Employed (2020 - 2026)
C4 Therapeutics (CCCC) recorded quarterly Return on Capital Employed of 35.94% in Q1 2026, up 12.89% quarter-over-quarter from 41.26% in Q4 2025, and up 374.0% on a YoY basis from 7.58% in Q1 2025.
C4 Therapeutics (CCCC) Return on Capital Employed (2020 - 2026) Analysis & Trends
C4 Therapeutics' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 35.94% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 374.0% year-over-year to 35.94%; the TTM figure through Mar 2026 stood at 35.94% (up 374.0% YoY), while the FY2025 annual figure was 35.86%, up 177.0% from the prior year.
- Return on Capital Employed was 35.94% for Q1 2026 at C4 Therapeutics, up from 41.26% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 20.04% in Q1 2022 to a low of 52.96% in Q3 2025.
- Historically, Return on Capital Employed has averaged 37.12% across 5 years, with a median of 37.66% in 2024.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed slumped 2140 bps in 2023, then soared 762 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 32.26% in 2022, then sank by 38 bps to 44.57% in 2023, then rose by 16 bps to 37.66% in 2024, then declined by 10 bps to 41.26% in 2025, then gained by 13 bps to 35.94% in 2026.
- The last three Return on Capital Employed figures came in at 35.94% (Q1 2026), 41.26% (Q4 2025), and 52.96% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | C4 Therapeutics | 520.69 Mn | 285.02 Mn | - | -35.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.94% |
| Dec 31, 2025 | -41.26% |
| Sep 30, 2025 | -52.96% |
| Jun 30, 2025 | -46.90% |
| Mar 31, 2025 | -39.68% |
| Dec 31, 2024 | -37.66% |
| Sep 30, 2024 | -35.59% |
| Jun 30, 2024 | -35.44% |
| Mar 31, 2024 | -40.62% |
| Dec 31, 2023 | -44.57% |
| Sep 30, 2023 | -43.21% |
| Jun 30, 2023 | -42.87% |
| Mar 31, 2023 | -35.93% |
| Dec 31, 2022 | -32.26% |
| Sep 30, 2022 | -24.67% |
| Jun 30, 2022 | -21.46% |
| Mar 31, 2022 | -20.04% |
| Dec 31, 2021 | -18.01% |
| Sep 30, 2021 | -18.27% |
| Jun 30, 2021 | -19.62% |